ADMA Biologics Reports Updated IVIG Process Study Results
ADMA Biologics says a three-lot study found its updated IVIG process removed clot-linked impurities and raised yield. No clotting events were reported through July 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.